We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Does Well in 2016: Reasons for Outperformance
Read MoreHide Full Article
New Jersey-based leading pharma company, Merck & Co. Inc.’s (MRK - Free Report) share price is up 11.8%, so far this year. This is impressive, given that the year was fraught with challenges for the pharma/biotech sector, which faced immense flak for steep drug prices. The company’s price movement compares favorably with the 6.1% fall for the Zacks categorized Large-Cap Pharma industry.
Let us analyze the reasons for the same.
Consistent Strong Results; Raised Guidance: Merck’s sales and profits have been relatively strong this year. It delivered positive earnings surprises in all the three quarters of 2016.
At the third-quarter call, Merck raised both its sales and earnings outlook for the year. Continued strong performance of newer drugs and cost-cutting initiatives should help it to achieve its guidance.
Keytruda, a Key Driver: Merck’s new products like cancer drug Keytruda have been contributing meaningfully to its top line, somewhat making up for the generic competition for several drugs. In October, Keytruda received an earlier-than-expected FDA approval for the first-line treatment of metastatic lung cancer. This is an important milestone for the company and Keytruda sales should improve sharply with the first-line NSCLC indication.
Importantly, Keytruda is being studied for more than 30 types of cancer. Merck is collaborating with several companies including Amgen, Inc. (AMGN - Free Report) , Incyte, GlaxoSmithKline plc (GSK - Free Report) and Pfizer Inc. (PFE - Free Report) among others, separately for the evaluation of the drug, in combination with other regimens. The last few months saw a series of positive news related to Keytruda, raising sales expectations for the drug.
New Drugs Doing Well: Apart from Keytruda, other new products are also performing well. Products that should contribute significantly to revenues include fertility drug Elonva, Simponi (inflammatory diseases), Dulera (asthma), and Daxas (chronic obstructive pulmonary disease), among others. Recently approved products include Zinplava (infection), Zepatier (HCV), Zontivity (anti-thrombotic), Belsomra (insomnia), Zerbaxa (antibiotic), Grastek, and Ragwitek.
Pipeline Matters: For any pharma or biotech company, the pipeline is of utmost importance and plays an important role in investment decisions. So, it always makes sense to take a look at a company’s pipeline.
Merck too has many pipeline candidates in advanced stages of development targeting multiple disease areas such as atherosclerosis, cancer, diabetes and cardiovascular diseases. It has more than 10 candidates in phase III development. Some of the important pipeline candidates include MK-0859 (anacetrapib - cholesterol management), verubecestat (Alzheimer’s disease), MK-8228 (letermovir, cytomegalovirus (CVM) infections) and MK-8835 (ertugliflozin, type II diabetes).
Cost Savings and Strategic Initiatives: In Oct 2013, Merck launched a strategic initiative to streamline its business. The company generated net cost savings of more than $2.5 billion in 2015 primarily by reducing marketing and administrative and R&D expenses.
Merck already has another global restructuring program in progress, which is aimed at reducing the cost structure and increasing efficiency. It intends to reduce the number of manufacturing sites, including animal health sites, and consolidate other facilities. The company expects annual savings of about $4.0−$4.6 billion once the restructuring program is completed.
Merck also divested segments like the Consumer Care business to focus on its core areas of expertise. The company is also returning value to shareholders in the form of share buybacks and dividends.
Conclusion
Like many of its peers, Merck is facing generic competition and pricing pressure for some products. Yet, we believe its diversified business model, deep pipeline and strong financial position will continue to help the company navigate tough times.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Merck (MRK) Does Well in 2016: Reasons for Outperformance
New Jersey-based leading pharma company, Merck & Co. Inc.’s (MRK - Free Report) share price is up 11.8%, so far this year. This is impressive, given that the year was fraught with challenges for the pharma/biotech sector, which faced immense flak for steep drug prices. The company’s price movement compares favorably with the 6.1% fall for the Zacks categorized Large-Cap Pharma industry.
Let us analyze the reasons for the same.
Consistent Strong Results; Raised Guidance: Merck’s sales and profits have been relatively strong this year. It delivered positive earnings surprises in all the three quarters of 2016.
At the third-quarter call, Merck raised both its sales and earnings outlook for the year. Continued strong performance of newer drugs and cost-cutting initiatives should help it to achieve its guidance.
Keytruda, a Key Driver: Merck’s new products like cancer drug Keytruda have been contributing meaningfully to its top line, somewhat making up for the generic competition for several drugs. In October, Keytruda received an earlier-than-expected FDA approval for the first-line treatment of metastatic lung cancer. This is an important milestone for the company and Keytruda sales should improve sharply with the first-line NSCLC indication.
Importantly, Keytruda is being studied for more than 30 types of cancer. Merck is collaborating with several companies including Amgen, Inc. (AMGN - Free Report) , Incyte, GlaxoSmithKline plc (GSK - Free Report) and Pfizer Inc. (PFE - Free Report) among others, separately for the evaluation of the drug, in combination with other regimens. The last few months saw a series of positive news related to Keytruda, raising sales expectations for the drug.
New Drugs Doing Well: Apart from Keytruda, other new products are also performing well. Products that should contribute significantly to revenues include fertility drug Elonva, Simponi (inflammatory diseases), Dulera (asthma), and Daxas (chronic obstructive pulmonary disease), among others. Recently approved products include Zinplava (infection), Zepatier (HCV), Zontivity (anti-thrombotic), Belsomra (insomnia), Zerbaxa (antibiotic), Grastek, and Ragwitek.
Pipeline Matters: For any pharma or biotech company, the pipeline is of utmost importance and plays an important role in investment decisions. So, it always makes sense to take a look at a company’s pipeline.
Merck too has many pipeline candidates in advanced stages of development targeting multiple disease areas such as atherosclerosis, cancer, diabetes and cardiovascular diseases. It has more than 10 candidates in phase III development. Some of the important pipeline candidates include MK-0859 (anacetrapib - cholesterol management), verubecestat (Alzheimer’s disease), MK-8228 (letermovir, cytomegalovirus (CVM) infections) and MK-8835 (ertugliflozin, type II diabetes).
Cost Savings and Strategic Initiatives: In Oct 2013, Merck launched a strategic initiative to streamline its business. The company generated net cost savings of more than $2.5 billion in 2015 primarily by reducing marketing and administrative and R&D expenses.
Merck already has another global restructuring program in progress, which is aimed at reducing the cost structure and increasing efficiency. It intends to reduce the number of manufacturing sites, including animal health sites, and consolidate other facilities. The company expects annual savings of about $4.0−$4.6 billion once the restructuring program is completed.
Merck also divested segments like the Consumer Care business to focus on its core areas of expertise. The company is also returning value to shareholders in the form of share buybacks and dividends.
Conclusion
Like many of its peers, Merck is facing generic competition and pricing pressure for some products. Yet, we believe its diversified business model, deep pipeline and strong financial position will continue to help the company navigate tough times.
Merck carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>